STOCK TITAN

Sarepta Therapeutics, Inc. - SRPT STOCK NEWS

Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a pioneering biopharmaceutical company primarily engaged in the discovery and advancement of RNA-targeted therapeutics. Headquartered in Cambridge, Massachusetts, Sarepta is dedicated to developing innovative treatments for a range of rare, infectious, and other challenging diseases.

Core Focus: Sarepta’s primary focus is on Duchenne Muscular Dystrophy (DMD), a severe type of muscular dystrophy. The company's lead product candidate, eteplirsen, is designed to skip exon 51 and potentially modify the progression of DMD. Alongside eteplirsen, Sarepta is working on other DMD drug candidates that target different exons.

Innovative Technology: The company leverages proprietary RNA-targeted technology platforms to create novel pharmaceuticals. This technology is pivotal in addressing diseases with high unmet medical needs.

Therapeutic Pipeline:

  • DMD Program: Focused on rapidly advancing exon-skipping drug candidates.
  • Infectious Diseases: Developing treatments for drug-resistant bacteria and other rare infectious diseases.

Financial Condition and Partnerships: Sarepta collaborates with third-party contractors for the manufacturing of its product candidates. This strategic approach allows the company to focus on innovation and development while ensuring efficient production processes. Despite most of its product candidates being in early developmental stages, Sarepta continues to secure funding and partnerships to support its ambitious research and development goals.

For more information, visit their official website at www.sarepta.com.

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, announced the granting of equity awards on June 28, 2024, as a material inducement for employment. These grants were approved under Sarepta's 2024 Employment Commencement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The awards consist of options to purchase 5,100 shares of common stock and 19,980 restricted stock units (RSUs) distributed among 23 new employees hired in June 2024. The stock options have an exercise price of $158.00 per share, equal to the closing price on the grant date. Vesting schedules are set for four years for both options and RSUs, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary

Sarepta Therapeutics announced an expanded FDA approval for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) in patients aged 4 and above. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients. The continued approval for non-ambulatory patients hinges on the results of a confirmatory trial. ELEVIDYS is contraindicated for patients with mutations in exon 8 and/or exon 9 of the DMD gene. Sarepta's ENVISION study aims to verify the clinical benefits of ELEVIDYS. The expansion represents a significant milestone for the Duchenne community and gene therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.14%
Tags
-
Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) announced on May 31, 2024, the issuance of equity awards as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). The awards were given to nine newly hired employees, granting a total of 8,975 restricted stock units (RSUs). The RSUs will vest in four equal installments annually over four years, subject to continuous employment. The awards were part of Sarepta's 2024 Employment Commencement Incentive Plan and approved by the Compensation Committee of the Board of Directors. No stock purchase options were granted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
none
Rhea-AI Summary

Sarepta Therapeutics, Inc. announced that Dr. Jerry R. Mendell, a gene therapy pioneer, was named to the inaugural TIME100 Health list for his contributions in neuromuscular disease treatment and gene therapy advancements, notably Duchenne muscular dystrophy. Dr. Mendell's lifelong dedication to genetic medicine has significantly impacted global health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
Rhea-AI Summary

Sarepta Therapeutics reported strong financial results for the first quarter of 2024, with net product revenues totaling $359.5 million, a 55% increase from the prior year. ELEVIDYS gene therapy generated $133.9 million in revenue. The company achieved GAAP earnings of $36.1 million and non-GAAP earnings of $78.2 million. Real-world evidence showed that eteplirsen treatment resulted in significant survival benefits for Duchenne muscular dystrophy patients. The FDA is reviewing an efficacy supplement to expand ELEVIDYS's indication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
-
Rhea-AI Summary

Sarepta Therapeutics, Inc. granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 24 new employees in April 2024, comprising options to purchase 0 shares of common stock and 17,090 restricted stock units. The options have an exercise price of $126.66 per share, with vesting schedules spread over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce its first quarter 2024 financial results on May 1, 2024, with a conference call to follow. The event will be webcast live on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
-
Rhea-AI Summary
Sarepta Therapeutics, Inc. granted equity awards to 8 new employees under its 2024 Employment Commencement Incentive Plan, totaling 5,100 stock options and 9,335 restricted stock units. The options have an exercise price of $129.46 per share, with vesting schedules over four years. This move aims to incentivize and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) will participate in fireside chats at two upcoming investor conferences in March 2024. The presentations will be webcast live and archived on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
conferences
Rhea-AI Summary
Sarepta Therapeutics, Inc. granted equity awards to 5 new employees as a material inducement to employment, including options to purchase 0 shares of common stock and 6,300 restricted stock units. The options have an exercise price of $127.90 per share, vesting over four years, while the RSUs vest yearly, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none

FAQ

What does Sarepta Therapeutics specialize in?

Sarepta Therapeutics specializes in the discovery and development of RNA-targeted therapeutics for rare, infectious, and other diseases, with a primary focus on Duchenne Muscular Dystrophy (DMD).

What is eteplirsen?

Eteplirsen is Sarepta Therapeutics' lead DMD product candidate, designed to skip exon 51 and potentially modify the progression of Duchenne Muscular Dystrophy.

Where is Sarepta Therapeutics headquartered?

Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

What kinds of diseases is Sarepta working on?

In addition to Duchenne Muscular Dystrophy, Sarepta is developing treatments for rare infectious diseases, including drug-resistant bacteria.

How does Sarepta manufacture its products?

Sarepta uses third-party contractors to manufacture its product candidates, allowing the company to focus on research and development.

What is the primary technology used by Sarepta?

Sarepta uses proprietary RNA-targeted technology platforms to develop its pharmaceutical products.

Are Sarepta's products approved for use?

Most of Sarepta's product candidates are currently in early stages of development and are not yet approved for widespread use.

How can I find more information about Sarepta Therapeutics?

You can find more information by visiting their official website at www.sarepta.com.

Is Sarepta involved in any partnerships?

Yes, Sarepta collaborates with third-party contractors and other entities to support its research and development efforts.

What is the latest news about Sarepta Therapeutics?

For the latest updates and news about Sarepta Therapeutics, please visit their official website or follow their stock news on financial websites.

Sarepta Therapeutics, Inc.

Nasdaq:SRPT

SRPT Rankings

SRPT Stock Data

14.83B
94.52M
4.41%
88.59%
10.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE